Search clinical trials for: OROS hydromorphone

Total 412 results

Mallinckrodt

Completed

A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain

Chronic Pain
Janssen Korea, Ltd., Korea

Completed

Clinical Usefulness and Quality of Life of OROS Hydromorphone in Patients Who Have Not Been Treated With a Strong Opioid

Pain

Korea, Republic of
Alza Corporation, DE, USA

Completed

A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain

Pain | Analgesics | Opioid
Janssen Korea, Ltd., Korea

Completed

Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients

Cancer Pain

Korea, Republic of
Janssen Korea, Ltd., Korea

Completed

An Observational Study to Investigate Clinical Usefulness of OROS Hydromorphone in Korean Cancer Patients

Pain
Alza Corporation, DE, USA

Completed

A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain

Pain | Analgesics, Opioid
Mallinckrodt

Completed

Study to Test the Effectiveness of Controlled-Release OROS® Hydromorphone HCl Compared to Placebo in Patients With Chronic Low Back Pain

Chronic Low Back Pain
Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer

Pain | Cancer
Janssen-Cilag International NV

Completed

Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee

Pain | Osteoarthritis, Knee | Osteoarthritis, Hip

United Kingdom, Romania, Slovakia, Czech Republic
Alza Corporation, DE, USA

Completed

Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)

Pain | Analgesics, Opioid
Alza Corporation, DE, USA

Completed

A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain

Pain, Postoperative | Analgesia | Orthopedic Procedures
Alza Corporation, DE, USA

Completed

A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain

Pain | Analgesics, Opioid
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.

Pain

France, Poland, Germany, Slovenia, Sweden, Czech Republic, Norway, Slovakia, Switzerland, Denmark
Alza Corporation, DE, USA

Completed

A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis

Osteoarthritis, Knee | Osteoarthritis, Hip
Alza Corporation, DE, USA

Completed

Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain

Pain | Analgesics, Opioid
Alza Corporation, DE, USA

Completed

Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain

Pain
Alza Corporation, DE, USA

Completed

An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)

Osteoarthritis, Knee | Osteoarthritis, Hip
Alza Corporation, DE, USA

Completed

Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back Pain

Low Back Pain
Alza Corporation, DE, USA

Completed

A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.

Pain | Analgesics, Opioid
Janssen Pharmaceutica

Terminated

Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain

Pain
Alza Corporation, DE, USA

Completed

An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg

Analgesia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
Alza Corporation, DE, USA

Completed

A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain

Low Back Pain
Mayo Clinic

Recruiting

A Study of Intrathecal Hydromorphone for Pediatric Idiopathic Scoliosis Repair

Pain Control

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Liposomal Bupivacaine With or Without Hydromorphone for the Improvement of Pain Control After Laparotomy in Patients With Gynecological Malignancies

Malignant Female Reproductive System Neoplasm

United States
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity
Johnson & Johnson Taiwan Ltd

Terminated

A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain

Cancer Pain
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Effect of Dose on the Pharmacokinetics of OROS Hydromorphone Under Fasted Conditions in Healthy Taiwanese Participants

Healthy Volunteers

Taiwan
Brigham and Women's Hospital

Terminated

Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study

Pain | Healthy | Pregnancy

United States
Thomas Jefferson University

Completed

Intrathecal Hydromorphone for Cesarean Section

Pain

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Massachusetts General Hospital

Withdrawn

Predicting Treatment Response to Stimulants in Adult ADHD Using Functional Magnetic Resonance Imaging

ADHD

United States
University of California, San Francisco
National Cancer Institute (NCI); Celgene Corporation; Westat; African Esophageal...

Recruiting

Treatment Outcomes of Esophageal Cancer

Esophageal Cancer

Tanzania, Kenya, Malawi
Shirley Ryan AbilityLab
Mallinckrodt

Completed

True Functional Restoration and Analgesia in Non-Radicular Low Back Pain (Covidien)

Low Back Pain

United States
University of Miami

Completed

CROS Application in CI (CROS)

Hearing Loss

United States
Advanced Bionics AG

Completed

Benefits of a Contralateral Routing of Signals (CROS) System in Unilateral CI-recipients

Cochlear Implants

France
University of British Columbia
Canadian Institutes of Health Research (CIHR); Providence Healthcare; Innerchange...

Completed

Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) (SALOME)

Heroin Dependence | Opioid Dependence

Canada
Dr. Anthony Ho

Recruiting

Epidural Versus Paravertebral Block Analgesia After Hepatectomy

Pain Control After Elective Hepatectomy

Canada
Mundipharma Research GmbH & Co KG

Completed

Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of Pain (HMX3501)

Constipation

Romania, Switzerland, Israel, Belgium, Germany, Australia, Austria, Czech Republic, Denmark, Finland, France, Netherlands, Poland, United Kingdom
Fujian Cancer Hospital

Completed

Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration

Cancer Pain

China
Nova Scotia Health Authority
Canadian Institutes of Health Research (CIHR); Nova Scotia Health Research... and other collaborators

Completed

Palliation of Dyspnea in Advanced Chronic Obstructive Pulmonary Disease (COPD) (ROS-003)

Chronic Obstructive Pulmonary Disease (COPD)

Canada
Hordinsky, Maria K., MD

Terminated

Topical Hydromorphone for Wound Healing

Wound Healing

United States
Parc de Salut Mar

Completed

Generation of Biological Samples Positive to Hydromorphone for Anti-doping Control (HM)

Healthy Volunteers

Spain
Azienda Ospedaliera Universitaria Integrata Verona

Recruiting

Osteoporosis and Fragility Fractures Among SLE Patients. (FRAIL Trial) (FRAIL)

Lupus Erythematosus, Systemic

Italy
Rennes University Hospital

Completed

Patient Reported Outcome (PRO) in CARDiac Surgery. (PRO-CARDS)

Cardiac Surgery

France
GenSight Biologics

Completed

REALITY LHON Registry (REALITY)

Leber Hereditary Optic Neuropathy

United States, France, Italy, Spain, United Kingdom
Cambridge University Hospitals NHS Foundation Trust

Withdrawn

Hearing Handicap in Patients With Single Sided Deafness

Hearing Loss

United Kingdom
Qianfoshan Hospital

Not yet recruiting

Hydromorphone for Perioperative Analgesia in Lung Tumor Ablation Parallel Controlled

Pulmonary Nodule | Ablation
Second Affiliated Hospital, School of Medicine,...

Unknown

The Effect of Esketamine on Patients Undergoing Tumor Surgery

Tumor Surgery

China
Virginia Commonwealth University

Terminated

Dose and Response of Intrathecal Hydromorphone in Patients Undergoing Cesarean Section at Virginia Commonwealth University Health System

Cesarean Section | Obstetric Anesthesia

United States

3

Subscribe